Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy

Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren’t responsive to first- or second-line therapies REDWOOD CITY, Calif., Feb. 1, 2024 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks